Premium
Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines? *
Author(s) -
Bezulier K.,
Fina F.,
Roussel M.,
Bun S.S.,
Ciccolini J.,
Martin P.M.,
Milano G.,
Aubert C.,
Barra Y.
Publication year - 2003
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1046/j.0269-4727.2003.00510.x
Subject(s) - fas ligand , apoptosis , cancer research , cytotoxicity , medicine , chemistry , programmed cell death , in vitro , biochemistry
Summary Various studies suggested that cytotoxicity induced by 5‐fluorouracil (5‐FU) is an apoptotic mechanism possibly mediated by the Fas/FasL system. In this preliminary work, we studied retrospectively the role the Fas/FasL expression as a predictive response factor with fluoropyrimidine‐based chemotherapies. We developed a real‐time PCR method for measuring Fas and FasL expression in various biopsies from patients treated with a FUFOL‐like protocol. No correlation was found between Fas or FasL expression and overall survival or partial response. However, the PCR assay was simple and convenient to use for quantitation of Fas/FasL in tumor biopsies.